Zikani Therapeutics Names Modur as Chief Scientific and Medical Officer
29 July 2020 - - US-based Zikani Therapeutics has appointed Vijay Modur, M.D., Ph.D., as its chief scientific and medical officer to lead the company in advancing its ribosome-modulating scientific platform into the next stage of drug development, the company said.

Modur was previously global project head in rare disease clinical development at Sanofi-Genzyme where he oversaw key functions responsible for advancing venglustat for the treatment of conditions caused by lysosomal dysfunction and other investigational therapies for several rare diseases, many with the potential for accelerated approval.

Before joining Sanofi-Genzyme, Dr. Modur served as chief medical officer and vice president of translational research for HTG Molecular.

Modur previously held clinical development leadership roles at Novartis and Merck (NYSE: MRK).

Modur earned his MBBS at Karnatak University, Dharwad, India and his Ph.D. in Experimental Pathology at the University of Utah. He completed his residency at Washington University, St. Louis where he served as Chief Resident, Laboratory Medicine. Dr. Modur is board certified in Clinical Pathology.

Ribosomal RNAs form the translation machinery that generates function proteins from genetic sequences. Ribosome modulation provides a therapeutic approach to addressing a number of diseases, but the development of disease-specific ribosome modulators has been a challenge.

Zikani Therapeutics is an emerging specialist in the science of ribosome modulation, leveraging its innovative TURBO-ZM chemistry technology platform to develop novel ribosome modulating agents as therapeutics for people with limited treatment options.